We are Minomic
Developer of novel prostate cancer diagnosticsWe have developed the MiCheck® test for prostate cancer.
Trials
Diagnosis
Validation
Distribution
Headquarters in Australia
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.
Our reach is global, through partnerships with universities, research institutes, and companies.
Our experience is backed up by independent experts in oncology, awards of multiple research grants and a major innovation prize, and investment backing of A$25 million to date.
Extensive intellectual property
Minomic owns an extensive patent estate protecting our distinctive technology. All the intellectual property relevant to our technology is owned by us.
Our investors and funding support
Minomic is an unlisted public company.
Over the past decade, Minomic has raised A$25m in funding. Investments have been made by MH Carnegie & Co through IIF (an Australian Government venture funding program) and by high net worth individuals.
Other sources of funding
include:
- an Australian Government Accelerating Commercialisation grant to help validate the MiCheck® test and support our rollout;
- Australian Government R&D Tax Incentives;
- a National Health and Medical Research Council Development Grant with QUT;
- ARC Hub award.
Contact us if you are interested in investing in the future of Minomic International.
Headquarters in Australia
Suite 2, Ground Floor, 75 Talavera Road, Macquarie Park, NSW 2113, Australia
Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here
Email
info@minomic.com
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.
Headquarters of Minomic
